Radiation dose escalation combined with hormone therapy improves outcome in localised prostate cancer

Acta Oncologica

Volumn 45, Issue 4, 2006, Pages 454-462

  Karlsdottir, Ása ^a,b   Paul Muren, Ludvig ^a,b   Wentzel Larsen, Tore ^b   Johannessen, Dag ^b   Bakke, August ^b   Øgreid, Per ^c   Johan Halvorsen, Ole ^d   Dahl, Olav ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, RADIATION; HORMONES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33745081215     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860500468943     Document Type: Article

References (53)

1. Cancer Registry of Norway. Cancer in Norway 2000. 2002.
2. Dahl O, Kardamakis D, Lind B, Rosenwald JC. Current status of conformal radiotherapy. Acta Oncol 1996;35(Suppl 8):41-57.
3. Vicini FA, Abner A, Baglan KL, Kestin LL, Martinez AA. Defining a dose-response relationship with radiotherapy for prostate cancer: Is more really better? Int J Radiat Oncol Biol Phys 2001;51(5):1200-8.
4. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001;166(3):876-81.
5. Horwich A, Wynne C, Nahum A, Swindell W, Dearnaley DP. Conformal radiotherapy at the Royal Marsden Hospital (UK). Int J Radiat Biol 1994;65(1):117-22.
6. Lilleby W, Dale E, Olsen DR, Gude U, Fossa SD. Changes in treatment volume of hormonally treated and untreated cancerous prostate and its impact on rectal dose. Acta Oncol 2003;42(1):10-4.
7. Shearer RJ, Davies JH, Gelister JS, Dearnaley DP. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. Br J Urol 1992;69(5):521-4.
8. TNM classification of malignant tumours. 4th ed., Geneva, Schweiz: International Union Against Cancer; 1992.
9. Mostofi FK, Sesterhenn IA, Sobin LH. Histological typing of prostate tumours. Geneva: World Health Organization; 1980.
10. Mellinger GT, Gleason D, Bailar J. The histology and prognosis of prostatic cancer. J Urology 1967;97:331-8.
11. Van der Kwast TH, Roobol MJ, Wildhagen MF, Martikainen PM, Maatanen L, Pihl CG, et al. Consistency of prostate cancer grading results in screened populations across Europe. BJU Int 2003;92(Suppl 2):88-91.
12. Karlsdottir A, Johannessen DC, Muren LP, Wentzel-Larsen T, Dahl O. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiother Oncol 2004;71(1):43-53.
13. Pickles T, Kim-Sing C, Morris WJ, Tyldesley S, Paltiel C. Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys 2003;57(1):11-8.
14. Kestin LL, Vicini FA, Martinez AA. Practical application of biochemical failure definitions: What to do and when to do it. Int J Radiat Oncol Biol Phys 2002;53(2):304-15.
15. Altman D. Practical statistics for medical research. Geneva: World Health Organization; 1991. p. 611.
16. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280(11):969-74.
17. Peschel RE, Colberg JW. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 2003;4(4):233-41.
18. Parker CC, Dearnaley DP. Radical radiotherapy for prostate cancer. Cancer Treat Rev 2003;29(3):161-9.
19. D'Amico AV, Chen M-H, Oh-Ung J, Renshaw AA, Cote K, Loffredo M, et al. Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. Int J Radiat Oncol Biol Phys 2002;54(2):436-41.
20. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carrol PR. The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 2004;22(11):2141-9.
21. Draisma G, Boer R, Otto SJ, Van der Cruijsen IW, Damhuis RA, Schroder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95(12):868-78.
22. Lujan M, Paez A, Miravalles E, Fernandez I, Llanes L, Berenguer. A prostate cancer detection is also relevant in low prostate specific antigen ranges. Eur Urol 2004;45(2):155-9.
23. Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer 2004;100(3):538-43.
24. Parker C. Active surveillance: Towards a new paradigm in the management of early prostate cancer. Lancet Oncol 2004;5(2):101-6.
25. Borre M, Nerstrom B, Overgaard J. The natural history of prostate carcinoma based on a Danish population treated with no intent to cure. Cancer 1997;80(5):917-28.
26. Iversen P, Tammela TL, Vaage S, Lukkarinen O, Lodding P, Bull-Njaa T, et al. A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6. Eur Urol 2002;42(3):204-11.
27. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347(11):781-9.
28. Douglas TH, McLeod DG, Mostofi FK, Mooneyhan R, Connelly R, Moul JW, et al. Prostate-specific antigen-detected prostate cancer (stage T1c): An analysis of whole-mount prostatectomy specimens. Prostate 1997;32(1):59-64.
29. Hanks GE, Hanlon AL, Pinover WH, al-Saleem TI, Schultheiss TE. Radiation therapy as treatment for stage T1c prostate cancers. World J Urol 1997;15(6):369-72.
30. Pound CR, Walsh PC, Epstein JI, Chan DW, Partin AW. Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer. World J Urol 1997;15(6):373-7.
31. Kupelian PA, Buchsbaum JC, Patel C, Elshatkh M, Reddy CA, Zippe C, et al. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys 2002;52(3):704-11.
32. Sandler HM, Dunn RL, McLaughlin PW, Hayman JA, Sullivan MA, Taylor JM. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 2000;48(3):629-33.
33. Vicini FA, Kestin LL, Martinez AA. The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. Cancer 2000;88(10):2305-18.
34. Pollack A, Hanlon AL, Movsas B, Hanks GE, Uzzo R, Horwitz EM. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003;57(1):19-23.
35. Hoffelt SC, Marshall LM, Garzotto M, Hung A, Holland J, Beer TM. A comparison of CT scan to transrectal ultrasound-measured prostate volume in untreated prostate cancer. Int J Radiat Oncol Biol Phys 2003;57(1):29-32.
36. Khuntia D, Reddy CA, Mahadevan A, Klein EA, Kupelian PA. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1-T3 prostate carcinoma in the prostate-specific antigen era: What should we expect? Cancer 2004;100(6):1283-92.
37. Duchesne GM. Radiation for prostate cancer. Lancet Oncol 2001;2(2):73-81.
38. Fossa SD, Lilleby W, Waehre H, Berner A, Torlakovic G, Paus E, et al. Definitive radiotherapy of prostate cancer: The possible role of staging lymphadenectomy. Int J Radiat Oncol Biol Phys 2003;57(1):33-41.
39. Zagars GK, Pollack A, Smith LG. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999;44(4):809-19.
40. Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, et al. Radical prostatectomy, external beam radiotherapy = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004;58(1):25-33.
41. Bergstrom P, Lofroth PO, Widmark A. High-precision conformal radiotherapy (HPCRT) of prostate cancer - a new technique for exact positioning of the prostate at the time of treatment. Int J Radiat Oncol Biol Phys 1998;42(2):305-11.
42. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 2000;355(9214):1491-8.
43. Bolla M, Collette L, Blank L, Warde P, Dubors JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase lll randomised trial. Lancet 2002;360:103-8.
44. Kupelian PA. External beam radiation therapy: Role of androgen deprivation. World J Urol 2003;21(4):190-9.
45. Gottschalk AR, Roach M 3rd. The use of hormonal therapy with radiotherapy for prostate cancer: Analysis of prospective randomised trials. Br J Cancer 2004;90(5):950-4.
46. D'Amico AV, Manola J, Loffredo M, Renshaw AA, Della-Croce A, Kantoff PW. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004;292(7):821-7.
47. Nguyen KH, Horwitz EM, Hanlon AL, Uzzo RG, Pollack A. Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer? Int J Radiat Oncol Biol Phys 2003;57(2):377-83.
48. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50(5):1243-52.
49. Pollack A, Hanlon A, Horwitz EM, Feigenberg S, Uzzo RG, Price RA. Radiation therapy dose escalation for prostate cancer: A rationale for IMRT. World J Urol 2003;21(4):200-8.
50. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53(5):1097-105.
51. Dearnaley DP, Hall E, Lawrence D, Huddart RA, Eeles R, Nutting CM, et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 2005;92(3):488-98.
52. Nilsson S, Norlen BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 2004;43(4):316-81.
53. DeWeese TL. Radiation therapy and androgen suppression as treatment for clinically localized prostate cancer: The new standard? JAMA 2004;292(7):864-6.